🏠
← All drugs
Fallopian Tube Cancer · Ovarian Carcinoma · Peritoneal Carcinoma · Squamous Cell Carcinoma of Head and Neck

TG4050

2 trials tracked · 1 active · last refreshed 2026-08-10

Summary

TG4050 is Transgene and NEC's personalized vaccine, built by predicting each patient's tumor-specific mutations with NEC's AI platform and encoding them into a myeloid-derived viral vector — a different delivery approach than the mRNA or peptide vaccines tracked elsewhere here. Its one active trial tests it after surgery in head and neck cancer, alongside standard treatment rather than in place of it.

Its earlier completed trial in ovarian carcinoma was the program's first proof-of-concept — head and neck cancer is now the lead indication being pursued, with ovarian carcinoma not currently in active recruitment despite still showing in the tracked condition list.

Trials

Click a row for what it's testing, where, and how many participants.

NCT IDTitlePhaseStatusStarted
NCT04183166 A Clinical Trial Evaluating TG4050 in Head and Neck Cancer Phase I, Phase II Active, not recruiting 2019-12-12

This is a multicenter, open-label, two arms, randomized, phase I/II study evaluating the safety and tolerability as well as some activity parameters of TG4050 in patients with squamous cell carcinoma of the head and neck (SCCHN).

Enrollment
80 (actual)
Sites
14 across 4 countries
Countries
France, Spain, United Kingdom, United States
Sponsor
Transgene

Primary outcome: Phase I: Safety and tolerability (Adverse Event reported per CTCAE v5)

NCT03839524 A Trial Evaluating TG4050 in Ovarian Carcinoma. Phase I Completed 2019-12-09

This is a multicenter, open-label, single arm phase I study evaluating the safety and tolerability as well as some activity parameters of TG4050 in patients with ovarian, fallopian or peritoneal serous carcinoma.

Enrollment
64 (actual)
Sites
6 across 2 countries
Countries
France, United States
Sponsor
Transgene

Primary outcome: Safety and Tolerability (Adverse Event Reported Per CTCAE v5)

This page is regenerated from ClinicalTrials.gov data and summarized once per refresh — nothing here is generated live when you visit. For informational purposes only; not medical advice.